Abstract
PurposeThis study aimed to explore the relationship between plakoglobin expression and clinical data in the patients with surgically resected lung adenocarcinoma.ResultsWith follow-up of median 50.14 months, the average PFS and OS were 16.82 and 57.92 months, respectively. In 147 patients, recurrence or death was observed in 131 patients. According to the log-rank test, low plakoglobin expression was a significant predictor for favorable DFS (P=0.006) and OS (P=0.043). For the analyses within subgroups, high plakoglobin expression was an independent factor for reducing DFS in non-metastatic patients with resected lung adenocarcinoma (P < 0.05). Moreover, high plakoglobin expression was associated with poor DFS even receiving adjuvant chemotherapy (P =0.028) and with a shorter DFS (HR, 2.01, 95%CIs, 1.35 to 2.97, P=0.001) and OS (HR, 1.94, 95%CIs, 1.12 to 3.37, P=0.019).Patients and methodsThe expression of plakoglobin in 147 primary tumor tissues was examined by using immunohistochemistry and clinical data were collected. The optimal cutoff value of immunoreactivity score (IRS) was calculated and used to divide all the patients into two groups: low-level group (IRS: 0-3, n=59) and high-level group (IRS: 4-12, n=88). Kaplan–Meier curves were applied to assess the plakoglobin expression and clinical variables. The univariate and multivariate Cox model analyses were performed to evaluate the effects of clinical factors and plakoglobin expression on disease-free survival (DFS) and overall survival (OS).ConclusionHigh plakoglobin expression is an independent negative prognostic factor for patients with surgically resected lung adenocarcinoma.
Highlights
Lung cancer is the leading common cause of cancerrelated deaths around the world [1]
According to the immunoreactivity score (IRS), we investigated the relationship between plakoglobin expression in patients with resected lung adenocarcinoma and their clinical outcomes
EGFR mutation detection was performed in 89 patients in the whole cohort
Summary
Lung cancer is the leading common cause of cancerrelated deaths around the world [1]. 80% of lung cancer cases belong to non-small-cell lung carcinoma (NSCLC) [2]. Lung adenocarcinoma is the most frequent subtype of NSCLC [3]. Curative-intent resection remains the backbone of therapeutics and increases the chance for survival in early diagnosed NSCLC [4]. Five-year survival rate ranges between 10% and 30% for patients with stage IIIA lung cancer [5]. Several randomized controlled trials reported that adjuvant chemotherapy substantially improved the survival in patients with resected NSCLC [6, 7]. Most patients eventually experience a recurrence of cancer despite potentially curative therapy or even after complete tumor resection, so the postoperative survival rate remains unsatisfactory.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
